In Q3 2024, OrbiMed Advisors held 97 positions worth $5.3B. They initiated 14 new positions and exited 54. Their largest holding was EWTX ($400.9M). Portfolio value grew +10.1% versus the prior quarter.
Frequently asked questions
What stocks did OrbiMed Advisors own in Q3 2024?
OrbiMed Advisors held 97 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include EWTX, SVA, LLY, BSX, ISRG. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was OrbiMed Advisors's portfolio worth in Q3 2024?
OrbiMed Advisors's tracked biotech portfolio was worth $5.3B across 97 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
What did OrbiMed Advisors buy in Q3 2024?
OrbiMed Advisors initiated 14 new positions in Q3 2024, including MBX, UTI, BIOA, PHAT, CGON and 9 more. They also increased 19 existing positions.
What did OrbiMed Advisors sell in Q3 2024?
OrbiMed Advisors fully exited 54 positions in Q3 2024, including TVTX, RVNC, MRSN, GHRS, EW and 49 more. They also trimmed 30 existing positions.
Is OrbiMed Advisors a biotech fund?
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Want AI analysis, insider signals, and catalyst overlays for OrbiMed Advisors?
View latest OrbiMed Advisors portfolio →